Regulatory Submission Quality Index KPI

Regulatory Submission Quality Index (RSQI) serves as a crucial performance indicator for organizations navigating complex regulatory environments.

High-quality submissions reduce the risk of delays, enhance compliance, and improve overall operational efficiency.

A robust RSQI correlates with better financial health, as it minimizes costly rework and accelerates time-to-market for new products.

Companies that prioritize RSQI often see improved stakeholder trust and stronger relationships with regulatory bodies.

By embedding this KPI within a comprehensive KPI framework, organizations can drive data-driven decisions that align with strategic goals.

Ultimately, RSQI influences business outcomes by ensuring that submissions meet or exceed target thresholds.

How Regulatory Submission Quality Index Connects to Your Strategy

Regulatory Submission Quality Index belongs to a single KPI group in KPI Depot's library: the Regulatory and Government Affairs Group, a set of fifty metrics assembled for a function that sits inside the General Counsel's purview. Within that KPI group it ranks twentieth. That is worth stating plainly rather than dressing up. This is a supporting metric, and the KPI group does not lead with it.

The eight metrics the KPI group ranks highest are Regulatory Compliance Rate, Regulatory Risk Assessment Completion Rate, Regulatory Audit Success Rate, Regulatory Fines and Penalties, Regulatory Cost of Non-Compliance, Regulatory Issue Resolution Time, Regulatory Change Management Effectiveness, and Regulatory Approval Success Rate. Two of those, the fines and the cost of non-compliance, are financial. The rest share this KPI's balanced scorecard placement in the internal process perspective, which says something about how the KPI group is built. It watches whether the regulatory machine is running, and it counts the money only after the machine has already failed.

There is a reason a quality index ranks below all eight, and the KPI group's own guidance says it out loud. That guidance recommends putting Regulatory Compliance Rate and Regulatory Issue Resolution Time into production first, because they rely on readily available data. Submission quality does not. No regulatory information management system emits it. Somebody has to define what a quality score is, score every submission against that definition, and hold the definition still long enough for a series to mean anything. Ranking here reflects what a KPI group can actually operate, not only what matters.

The internal process placement makes this a leading metric, but it leads into an operational consequence rather than a financial one. Weak submissions produce questions. Questions produce rework and delay. Delay pushes out an approval date and everything that depends on it. What weak submissions almost never produce is a fine, so a customer expecting this index to predict Regulatory Fines and Penalties or Regulatory Cost of Non-Compliance, ranked fourth and fifth, will wait a long time. Its cost lands as cycle time, and cycle time is charged to a different budget.

The sharpest tension in this KPI group is with Regulatory Document Submission Timeliness. It is not in the top eight, but the KPI group's OKR material puts the two in the same objective, and the KPI group's best practice guidance is explicit that both have to be measured together to prevent costly back-and-forth with agencies. The conflict is the one every deadline creates. The filing date is fixed by a statute or a commitment, the content is not finished, and the only compressible step left is internal review. Timeliness is cheap to measure and shows up on a calendar. Quality is expensive to measure and shows up months later in somebody else's inbox. The cheap metric wins that argument unless both sit on the same report.

Then there is Regulatory Approval Success Rate, ranked eighth, which quietly absorbs quality failures. A submission that drew a heavy deficiency letter, consumed months of response work, and was eventually approved is recorded as a success beside one that cleared on the first pass. An organization can hold its approval rate flat for years while its submission quality erodes, by spending more on responses each cycle. That spending is visible, but it surfaces in Regulatory Issue Resolution Time, ranked sixth, not in the approval column. Read the two beside each other or the compensation stays hidden.

The last tension is with the metric at the top. The KPI group already warns about a version of it, telling teams to track Regulatory Compliance Rate against Regulatory Audit Success Rate and to treat any divergence as an audit-readiness problem, because documented compliance and verified compliance are different things. The same gap runs through this KPI, and wider, because the index is scored inside the building while the deficiencies are cited outside it. When the internal score improves and the regulator's questions do not slow down, believe the regulator.

Measuring Regulatory Submission Quality Index in Practice

This page carries two metrics under one name, and they are not versions of each other. The definition measures quality by the number of follow-up questions or deficiencies cited by regulators: a count of bad outcomes, produced by someone outside the organization, well after filing, where lower is better. The canonical formula is the sum of submission quality scores divided by the number of submissions: a mean of internal assessments, produced by the organization itself, at or before filing, where higher is better. Different producer, different timing, different direction of good. They can move against each other in the same quarter with neither being wrong, which is exactly what happens when a scoring rubric tightens while a regulator gets more demanding. Decide which metric you are running before anything else, and print the answer on the report.

An Index With Undefined Components Is Not a Measurement. "Submission quality score" names nothing until somebody writes down what goes into it and how much each part counts. Completeness against the agency's checklist, internal QC defects by module, data integrity findings, adherence to the publishing specification, consistency between a clinical summary and the datasets underneath it: all of these are plausible components, and organizations pick different sets. Until the components and their weights live in a versioned document that outlives the person who invented them, the number summarizes whoever happened to score it that month. Write it down first, then measure. An index defined after the fact is a narrative with a decimal point.

Reweighting Breaks the Series. A composite is comparable to itself only while its weights hold. Raise the weight on publishing compliance because that is where the pain is this year, and the entire history changes meaning, including the part already shown to a board. The next quarter's improvement is then part behaviour and part arithmetic, with no way to separate them after the fact. Two disciplines make this survivable. Restate prior periods under the new weights every time you change them, and keep the component scores as raw data so any weighting can be recomputed later. Teams that store only the composite can do neither, and they usually discover this during the meeting where someone asks what changed.

Deficiency Counts Measure the Regulator's Attention. The definitional side has its own problem, no smaller. A count of cited deficiencies is co-produced by the submission and by the reviewer. Review intensity varies by product, by pathway, by individual reviewer, by division, and by agency, and it shifts over time as an agency's priorities move. A first-in-class product draws more questions than a well-trodden generic of identical quality. An agency under public pressure in a therapeutic area asks more questions that year, of everybody. Two identical submissions filed with two different regulators come back with different counts, so a cross-jurisdiction comparison of this metric is largely a comparison of regulators. Segment by regulator and by pathway always, and resist the request to pool them into one organizational number, because that number is an average of incompatible processes.

Severity Collapses Into the Tally. A count treats a request to clarify a table footnote and a major objection to the study design as one unit each. They are not one unit each. An organization that runs this metric as a count will eventually optimize the easy end, because it is the cheap end: a QC pass that eliminates typographical queries moves the number and changes nothing about the risk of refusal. Weight by severity using the agency's own categories where they exist, major objection against other concern, deficiency letter against information request, and report the severe count as its own line rather than folding it into a weighted total where it can be diluted by trivia.

The Lag, and Why a Fast Series Is Usually Incomplete. Questions arrive long after the submission goes in, sometimes the better part of a year later, and they arrive in waves rather than all at once. The current period's index is therefore provisional. It settles only when the review closes. This produces a specific and extremely common misreading: recent periods look better than older ones because the older ones have accumulated all their questions and the recent ones have not. A series that improves smartly at its right-hand end is nearly always incomplete data rather than progress. Two habits fix it. Anchor every question to the submission's filing period rather than to the period it arrived in, and mark any period with open reviews as provisional on the face of the report. Some organizations go further and publish a cohort only once every review in it has closed, which makes the number late and true.

Censoring on Withdrawals. Withdrawn and abandoned submissions are not missing at random. They are disproportionately the bad ones. A submission pulled after a devastating first round leaves the denominator and takes its deficiencies with it, and the surviving population then looks healthier than the work actually was. The rule has to be set in advance: either keep withdrawals in, carrying the deficiencies they accumulated up to the withdrawal, or report them as a separate line beside the index. Dropping them quietly is the easiest way in existence to produce a flattering series, and it is usually done by accident, through a join that only picks up closed approvals.

Small Denominators. Most organizations do not file many submissions in a quarter. A mean over a handful of items is dominated by the worst one in it, so the index swings on a single filing and a committee reads the swing as a trend. Report the submission count beside the index every single time. Use a rolling window long enough to hold a sensible number of filings. Show the distribution, not only the mean, because with few enough items the distribution is the honest presentation and the mean is decoration.

Self-Assessment. Internal quality scores are usually assigned by the people who prepared the submission, or by a quality group reporting to the same executive as the preparers. That is a conflict, and it does not require anyone to be dishonest to bend the number. A group judged on the index it assigns drifts toward generosity over quarters, imperceptibly, one defensible judgement at a time. The countermeasures are structural rather than motivational: score against a published rubric with worked examples, have a second scorer review a blind sample, and calibrate the internal score against the external outcome once each review closes. If the internal index and the regulator's questions stop agreeing, the rubric is the thing that is broken.

First Cycle Against Post-Response. An approval is an approval, so a submission that needed an enormous response package and one that sailed through look identical at the end. That is precisely what an end-state quality measure cannot see, and it is the part worth seeing, because the response effort is where the cost sits. Measure quality at the first cycle, and track the response burden separately: rounds of questions, volume of response documentation, elapsed days in clock stops. Those three beside a first-cycle outcome describe what the filing actually cost. The approval date alone describes nothing except that it eventually happened.

Normalization. A larger submission attracts more questions than a smaller one at the same quality, simply because there is more of it to read. Deficiencies per submission, per module, and per volume of documentation are three different metrics. Per submission is defensible only when submissions are comparable in scope, and across pathways they are not, which is another reason the pooled organizational figure is weaker than the segmented one.

Where the data lives, and how to join it honestly. The regulatory information management system holds the submissions, filing dates, pathways, and jurisdictions. The correspondence or agency interaction log holds the questions, information requests, and deficiency letters. The electronic publishing system holds validation errors and specification failures, which are the most objective component available for the internal index and the one most often ignored. The internal QC records hold the component scores. The decision itself sits in the agency's correspondence. The join is harder than it looks because the unit of analysis is unstable: one submission carries many sequence numbers, amendments, and supplements, and a question raised against an amendment can be attributed to the amendment or back to the original filing. Both choices are defensible and they produce different indexes. Pick one, write it down, and make sure the reporting query implements the one you wrote down.

Segmentation that changes the answer: by regulator and jurisdiction, by pathway or submission type, by product novelty, by whether a pre-submission meeting took place, and by the team or site that prepared the filing. The last cut carries the most management value and is left out the most often, because it names names.

Common Pitfalls

Many organizations overlook the importance of a comprehensive review process, which can lead to submission errors that jeopardize compliance.

• Relying solely on automated systems without human oversight can result in critical errors. While automation enhances efficiency, it cannot replace the nuanced understanding that experienced professionals bring to the submission process.
• Neglecting to train staff on regulatory changes leads to outdated practices. Continuous education is essential for maintaining high submission quality and staying compliant with evolving standards.
• Failing to incorporate feedback from regulatory agencies can perpetuate mistakes. Organizations must actively seek and act on insights from past submissions to enhance future performance.
• Overcomplicating submission formats can confuse reviewers and delay approvals. Clear, concise documentation is vital for ensuring that submissions are easily understood and processed.

Improvement Levers

Enhancing RSQI requires a multifaceted approach that prioritizes clarity, accuracy, and continuous learning.

• Establish a cross-functional review team to ensure submissions are comprehensive and accurate. Diverse perspectives can identify potential issues before they become problematic.
• Implement regular training sessions focused on regulatory updates and best practices. Keeping staff informed fosters a culture of compliance and improves submission quality.
• Utilize data analytics to track submission outcomes and identify trends. Quantitative analysis can reveal patterns that inform process improvements and enhance overall quality.
• Solicit feedback from regulatory agencies post-submission to identify areas for improvement. Constructive criticism can guide future submissions and strengthen relationships with regulators.

KPI Depot is trusted by consulting, strategy, finance, and analytics teams at leading organizations worldwide, including those listed below.

Regulatory Submission Quality Index Benchmarks

We have 5 relevant benchmarks in our benchmarks database.

Browse the Top Benchmarked KPIs in Regulatory and Government Affairs Group

Reading the Benchmarks for Regulatory Submission Quality Index

Five source records are tracked for this page, and they come from two organizations. Four are from the U.S. Food and Drug Administration. One is from Health Canada. Rows that share an organization share a review process, a statutory framework, a reviewer pool, and a counting convention, so the four FDA rows cannot corroborate each other. They are one regulator's reporting, split across four documents. The set holds two independent readings, not five, and a customer who counts rows instead of organizations will overestimate how much evidence is here.

Both organizations are regulators reporting on their own review outcomes. That is the most consequential fact about this source set. Not one row is a company reporting an internal submission quality index. Every figure describes what a regulator did with the applications it received, which lands on the definitional half of this KPI, the deficiencies and follow-up questions cited by regulators, and nowhere near the formula half, a mean of internally assigned submission quality scores. Anyone planning to judge an internal scoring program against these sources is comparing two different quantities that happen to share a page.

No row records a formula. The formula field is empty on all five, so none of them states how its figure was computed. What they do carry is a statement type, and there the set splits. Four rows are recorded as a first-cycle approval rate. One, the FDA row covering a recent fiscal year, is recorded as a first-cycle bioequivalence adequacy rate. Those are different verdicts. First-cycle approval judges the whole application. First-assessment adequacy judges one component, reviewed by one office. A bioequivalence section can be entirely adequate while the application goes nowhere, for reasons sitting in chemistry, manufacturing, labelling, or a facility inspection. Lining those two up as though they measure one construct is the easiest mistake available with this set.

Population is where the FDA rows come apart. One is scoped to abbreviated applications assessed by a single office. One to a narrow and technically difficult product class, modified release tablets, as original applications. One to novel drugs, which travel a different pathway with different review divisions, different statutory clocks, and far more sponsor contact before filing. And one is scoped to abbreviated application approvals rather than to abbreviated applications submitted. That last distinction deserves a pause. A denominator of approvals excludes every application that was never approved, which removes the worst submissions from the calculation entirely. A rate computed over survivors is not a rate computed over filings, and nothing in the row label warns you which one you are holding.

The Health Canada row is scoped to new generic drug submissions, which is closer to the abbreviated application rows than to the novel drug row. Closer is not comparable. A different regulator runs a different review against different filing standards and asks questions at its own rate, so the difference between that row and any FDA row is partly a difference in regulators rather than in submissions.

Time period varies in kind, not only in length. Two rows record no time period at all, which means their figures cannot be placed on a timeline even in principle. One covers a single fiscal year. One covers a single calendar year. The Health Canada row covers a five-year fiscal span, which is a multi-year average and cannot be set against a single-year figure without smoothing away the variation someone would be looking for. Fiscal and calendar boundaries alone shift submissions between buckets.

Vintage is spread out. The oldest row is congressional testimony from several years before the others. The newest is a recent annual report. Across that stretch the generic drug user fee program changed review practice and sponsor obligations, and review conventions moved with it. An older row and a newer row from the same agency, wearing the same statement type label, are not guaranteed to be counting the same way.

Sample size appears on two rows and is missing from three. A blank sample size is information, not a formatting gap: for those rows you cannot tell whether the figure rests on several hundred applications or on a handful, and with a handful one unusual filing sets the result.

Company size is blank on every row without exception. That absence matters here more than most. The question an internal team most wants answered is whether a small filer with a thin regulatory affairs function draws more deficiencies than a large one with a dedicated publishing group. Nothing in this source set answers it, and no amount of careful reading will make it answer it.

Industry is pharmaceutical throughout, mostly generic pharmaceuticals, with the two recent rows scoped to pharmaceuticals more broadly. Geography is the United States on four rows and Canada on one. The name of this KPI is industry-neutral and jurisdiction-neutral. The tracked evidence is neither. A customer filing with a banking supervisor, an energy regulator, a telecommunications authority, or a medical device body will find nothing directly transferable in this set and should not assume the shape of a drug review carries across.

Four things have to be established before any external figure for this metric goes into a board pack, and the tracked rows show how often they go unrecorded: what the denominator counted, applications filed or applications approved; whether a review cycle is defined the same way; whether the figure describes a regulator's outcome or a sponsor's own score; and what period basis produced it. A row missing one of those is not comparable to your own. A row missing all of them is a number, not a benchmark.

OKRs That Use Regulatory Submission Quality Index

The KPI group's OKR material names this KPI directly in one worked objective: Accelerate and improve regulatory submissions to gain faster approvals. There it sits beside Regulatory Document Submission Timeliness and Regulatory Approval Success Rate, on the stated logic that documents which are both on time and clean shorten review cycles and cut the wait for products or operations that need an approval. As a key result, frame it directionally and in both halves at once: lift the submission quality index and reduce the deficiencies cited per submission, without giving up filing schedule. Both halves have to be named, because the objective is otherwise winnable by filing late and clean, or on time and thin.

Two conditions make that key result honest rather than decorative. Freeze the index definition and its weights for the whole OKR period and publish them, or the target can be hit by rescoring rather than by better work. And report the regulator's own count for the same submissions as a separate key result rather than blending it into the index, since a quarter where the internal score climbs and the agency's questions do not thin out is a rubric problem wearing a win's clothing. There is also a timing constraint that most teams discover too late. Questions arrive months after filing, so an OKR period is usually shorter than a review cycle, and the cohort you can actually score is the one filed before the period began. Write the key result against that cohort deliberately instead of pretending the current quarter's filings have been judged.

A second objective in the same KPI group uses this KPI differently. Improve response capabilities to regulatory changes and emerging risks runs on Regulatory Change Response Time, Regulatory Risk Assessment Completion Rate, and Regulatory Change Management Effectiveness. Each of those measures whether the organization noticed a change and processed it internally. None shows whether the change reached the documents that went out the door. Submissions filed into a freshly revised requirement are the ones that draw deficiencies, so a quality index restricted to filings made after a given change took effect is the check on whether change management landed where it counts. The directional key result: cut the deficiencies attributable to recently changed requirements across submissions filed after the change date, and hold it flat or better on everything else.

The KPI group's own best practice guidance supports two rules across both framings. It tells teams to measure submission quality alongside timeliness, which is the first objective in one sentence. And it tells teams to align key results with jurisdiction-specific compliance rather than one blended figure, which matters more for this KPI than for most, because a deficiency count reflects the regulator as much as it reflects the filing. Set the target per regulator and accept that the targets will differ.

One thing not to do. Do not make this index a standalone key result owned by the same group that assigns the scores. That is a target set on a self-assessment, and it will be met.

See OKR Examples for Regulatory and Government Affairs Group

Free Whitepaper

Want to achieve performance excellence in Regulatory and Government Affairs Group? Download our in-depth whitepaper: Definitive Guide to Regulatory and Government Affairs Group KPIs.

Download the Free Guide

KPI Categories

This KPI is associated with the following categories and industries in our KPI database: